The world-leading global gene editing company is pioneering personalised medicines across a range of disease areas and is growing fast around the world. Horizon has become the planet’s definitive cell builder.
Its powerful and flexible platform allows researchers to develop cell models that drive understanding of a disease, create novel molecular, cellular and gene therapies and improve the ability to perform genome surgery.
It is doubling its footprint and growing headcount at an expanded Cambridge HQ and scaling in Asia. The company is sitting on a multimillion dollar milestone mountain and in May expanded its technology suite to set up a multimillion dollar boom in immuno-oncology.